Conducts multi-target oral macrocyclic peptide research with Unnatural Products. Evidence supporting marketed antibody products does not raise the evidence grade of the macrocycle program.
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Disease tags match recorded text mentions and require program-level verification.
Technology, programs & evidence
Conducts multi-target oral macrocyclic peptide research with Unnatural Products. Evidence supporting marketed antibody products does not raise the evidence grade of the macrocycle program.
Program / service
Target / indication
Representative stage
Evidence & scope
UNP–argenx oral macrocycle program
Not disclosed · Not disclosed
未披露
Quantitative human results not confirmed in this review
Related news & literature
Company-name matches are discovery leads; verify entity identity and transaction roles in the original source.
Unnatural Products closed a $45 million Series B led by The Venture Collective, with argenx, Droia, and existing investors participating. Funding supports its computational design, automated chemistry, high-throughput screening platform, and macrocyclic peptide pipeline. The oral-delivery strategy remains a development objective; this financing announcement does not establish human oral efficacy for a newly disclosed candidate.
Ahead of the AHA meeting, an original report reviewed enlicitide analyses across PREVENT cardiovascular risk groups and an open-label extension. LDL cholesterol reductions were broadly consistent across risk categories and persisted through Week 104. The extension selected participants who had tolerated and adhered to treatment and lacked a control group, limiting generalization of its long-term findings.
Aurinia reported LUPKYNIS net product sales of $232.4 million for the nine months ended September 30, 2026, up 18%, including $79.4 million in the third quarter, up 12%. Total company revenue also includes licensing, collaboration, and royalty income. These are commercialization results for an approved oral cyclic peptide, rather than a new indication approval or clinical endpoint readout.
A new review connects peptide structure, formulation, screening, and pharmacokinetic testing in an evidence-based framework for oral drug discovery. It distinguishes architecture-led libraries, oral optimization of existing hits, and hybrid approaches. The scope includes cyclic and noncyclic peptides; the proposed framework organizes development evidence rather than demonstrating a new therapy or clinical benefit.
Research this company together
Discussions are for signed-in members. Personal notes remain separate from company research.
